Biosense Webster News & Events

Johnson & Johnson Highlights Favorable 12-Month Interim Results for the VARIPULSE Platform at EHRA 2026

VARIPULSE

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter

Johnson & Johnson MedTech Presents Pivotal 12-Month Effectiveness and Safety Data from SmartfIRE Study at 2025 EHRA Congress 

Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter

Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter

10 January 2025

VARIPULSE™

The Evolving Landscape of Atrial Fibrillation Ablation: VARIPULSE™ Launches in European Hospitals

22 October 2024

Johnson & Johnson MedTech receives CE Mark for OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias

Biosense Webster Completes Enrollment of Omny-IRE Clinical Trial Investigating the OMNYPULSE™ Large-tip Focal Pulsed Field Ablation Catheter

How Our Innovation Restored an Employee’s Heartbeat

How Our Innovation Restored an Employee’s Heartbeat

Biosense Webster Presents Late-Breaking Data from admIRE Clinical Trial at the Heart Rhythm Society Annual Meeting

First Look at Data on Biosense Webster Dual Energy THERMOCOOL SMARTTOUCH™ SF Platform for Atrial Fibrillation Presented at EHRA Congress

First Look at Data on Biosense Webster Dual Energy THERMOCOOL SMARTTOUCH™ SF Platform for Atrial Fibrillation Presented at EHRA Congress

Biosense Webster inspIRE clinical study demonstrates 80% freedom from atrial arrhythmia recurrence at 12 months

VARIPULSE Platform

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform

29 February 2024

VARIPULSE™ variable-loop multielectrode catheter

Biosense Webster Announces Regulatory Approval of VARIPULSE™ Pulsed Field Ablation (PFA) Platform in Japan

09 January 2024

Biosense Webster Completes Enrollment in Pivotal Trial Evaluating PFA and RF Dual Energy Catheter for Patients with Atrial Fibrillation in Europe

Biosense Webster Begins SmartfIRE Clinical Trial to Evaluate its First Dual Energy Catheter to Treat Atrial Fibrillation

Biosense Webster Launches HELIOSTAR™ in Europe

Biosense Webster Launches HELIOSTAR™ in Europe, the First Radiofrequency Balloon Ablation Catheter, Enabling Physicians to Perform More Efficient Cardiac Ablations

12 October 2022

Biosense Webster Launches the OCTARAY™ Mapping Catheter with TRUEref™ Technology

06 September 2022

CARTO PRIME® Module hero image

Biosense Webster Launches CARTO® 3 System Version 7 and the CARTO PRIME™ Mapping Module to Advance Treatment of Complex Arrhythmias

QDOT Micro® Catheter hero image

Biosense Webster Receives CE Mark Approval for QDOT MICRO®, The World’s First Very High Power, Short Duration Ablation Catheter

Reducing Stroke Risk with Atrial Fibrillation Treatment

Reducing Stroke Risk with Atrial Fibrillation Treatment

committed to community hero image

Commited to our Community

Biosense Webster launches a two-pronged initiative to tackle the new millennium epidemic of Atrial Fibrillation

18 November 2019

Burden of AFib through awareness June4 2019

Beating the burden of AFib through awareness

radiofrequency ablation success heart

New Data Demonstrates >90% Year 1 Success Rate for Radiofrequency Ablation in Treating Patients with Atrial Fibrillation

22 November 2017